skip to main content

S. 982: ICBM Act


We don’t have a summary available yet.

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress, and was published on Mar 25, 2021.


Investing in Cures Before Missiles Act of 2021 or the ICBM Act

This bill addresses the transfer and use of funds intended for defense programs. Specifically, the bill requires the Department of Defense (DOD) to transfer $1 billion of unobligated balances intended for its ground-based strategic deterrent program to the National Institute of Allergy and Infectious Disease for research on the development of a universal coronavirus vaccine.

Next, the bill requires the Department of Energy to transfer unobligated balances for the W87-1 warhead modification program administered by the National Nuclear Security Administration to the Centers for Disease Control and Prevention to research and combat emerging and zoonotic infectious diseases.

The bill prohibits the use of funds authorized for FY2022 for the ground-based strategic deterrent program or the W87-1 warhead modification program.

Finally, the bill requires DOD to enter into a contract with the National Academy of Sciences to study extending to 2050 the life of Minuteman III intercontinental ballistic missiles.